Lisata Therapeutics Net Income vs. Total Debt
| LSTA Stock | USD 4.64 0.06 1.31% |
Net Loss | First Reported 1994-06-30 | Previous Quarter -4.7 M | Current Value -4.2 M | Quarterly Volatility 7.5 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.13 | 0.14 |
|
|
For Lisata Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lisata Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lisata Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lisata Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lisata Therapeutics over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. Expected growth trajectory for Lisata significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Lisata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lisata Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lisata Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lisata Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Lisata Therapeutics Total Debt vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lisata Therapeutics's current stock value. Our valuation model uses many indicators to compare Lisata Therapeutics value to that of its competitors to determine the firm's financial worth. Lisata Therapeutics is rated fifth overall in net income category among its peers. It is rated below average in total debt category among its peers . At present, Lisata Therapeutics' Net Loss is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lisata Therapeutics' earnings, one of the primary drivers of an investment's value.Lisata Total Debt vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Lisata Therapeutics |
| = | (19.98 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Lisata Therapeutics |
| = | 137 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Lisata Total Debt vs Competition
Lisata Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 112.56 Million. Lisata Therapeutics adds roughly 137,000 in total debt claiming only tiny portion of equities under Health Care industry.
Lisata Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lisata Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lisata Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Lisata Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Lisata Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -93.2 K | -97.8 K | |
| Operating Income | -20.2 M | -21.2 M | |
| Income Before Tax | -18.7 M | -19.6 M | |
| Total Other Income Expense Net | 1.5 M | 1.5 M | |
| Net Loss | -18 M | -18.9 M | |
| Income Tax Expense | -718.2 K | -754.1 K | |
| Net Loss | -18 M | -18.9 M | |
| Net Loss | -24.7 M | -26 M | |
| Change To Netincome | 5.2 M | 5.5 M | |
| Net Loss | (2.76) | (2.90) | |
| Income Quality | 0.87 | 0.92 | |
| Net Income Per E B T | 0.87 | 0.51 |
Lisata Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lisata Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lisata Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lisata Therapeutics' important profitability drivers and their relationship over time.
Lisata Therapeutics Earnings Estimation Breakdown
The calculation of Lisata Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Lisata Therapeutics is estimated to be -0.25625 with the future projection ranging from a low of -0.2725 to a high of -0.24. Please be aware that this consensus of annual earnings estimates for Lisata Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.27 Lowest | Expected EPS | -0.24 Highest |
Lisata Therapeutics Earnings Projection Consensus
Suppose the current estimates of Lisata Therapeutics' value are higher than the current market price of the Lisata Therapeutics stock. In this case, investors may conclude that Lisata Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Lisata Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 3 | 68.49% | 0.0 | -0.25625 | -2.13 |
Lisata Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Lisata Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Lisata Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Lisata Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Lisata Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Lisata Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Lisata Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Lisata Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Lisata Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | -0.59 | -0.49 | 0.1 | 16 | ||
2025-08-07 | 2025-06-30 | -0.64 | -0.54 | 0.1 | 15 | ||
2025-05-07 | 2025-03-31 | -0.53 | -0.55 | -0.02 | 3 | ||
2025-02-26 | 2024-12-31 | -0.76 | -0.55 | 0.21 | 27 | ||
2024-11-01 | 2024-09-30 | -0.77 | -0.59 | 0.18 | 23 | ||
2024-08-12 | 2024-06-30 | -0.76 | -0.61 | 0.15 | 19 | ||
2024-05-09 | 2024-03-31 | -0.72 | -0.65 | 0.07 | 9 | ||
2024-02-29 | 2023-12-31 | -0.89 | -0.66 | 0.23 | 25 | ||
2023-11-02 | 2023-09-30 | -0.93 | -0.65 | 0.28 | 30 | ||
2023-08-14 | 2023-06-30 | -0.7 | -0.5 | 0.2 | 28 | ||
2023-05-09 | 2023-03-31 | -0.81 | -0.77 | 0.04 | 4 | ||
2023-03-30 | 2022-12-31 | -1.01 | -0.76 | 0.25 | 24 | ||
2022-11-10 | 2022-09-30 | -0.9 | -7.88 | -6.98 | 775 | ||
2022-08-04 | 2022-06-30 | -1.45 | -1.65 | -0.2 | 13 | ||
2022-05-05 | 2022-03-31 | -1.45 | -1.05 | 0.4 | 27 | ||
2022-03-22 | 2021-12-31 | -2.17 | -1.65 | 0.52 | 23 | ||
2021-11-04 | 2021-09-30 | -2.25 | -1.8 | 0.45 | 20 | ||
2021-08-05 | 2021-06-30 | -2.17 | -1.5 | 0.67 | 30 | ||
2021-05-06 | 2021-03-31 | -1.27 | -2.85 | -1.58 | 124 | ||
2021-02-25 | 2020-12-31 | -3.8 | -4.2 | -0.4 | 10 | ||
2020-11-05 | 2020-09-30 | -4.35 | -4.35 | 0.0 | 0 | ||
2020-08-13 | 2020-06-30 | -5.81 | 7.5 | 13.31 | 229 | ||
2020-05-07 | 2020-03-31 | -4.35 | -5.7 | -1.35 | 31 | ||
2020-03-05 | 2019-12-31 | -5.17 | -7.05 | -1.88 | 36 | ||
2019-11-06 | 2019-09-30 | -6.45 | -7.05 | -0.6 | 9 | ||
2019-08-08 | 2019-06-30 | -6.67 | -7.35 | -0.68 | 10 | ||
2019-05-09 | 2019-03-31 | -6.37 | -6.6 | -0.23 | 3 | ||
2019-03-14 | 2018-12-31 | -6.6 | -5.4 | 1.2 | 18 | ||
2018-11-08 | 2018-09-30 | -8.4 | -5.4 | 3.0 | 35 | ||
2018-08-09 | 2018-06-30 | -9.6 | -8.55 | 1.05 | 10 | ||
2018-05-10 | 2018-03-31 | -10.05 | -7.8 | 2.25 | 22 | ||
2018-03-22 | 2017-12-31 | -10.42 | -6.15 | 4.27 | 40 | ||
2017-11-09 | 2017-09-30 | -11.62 | -5.7 | 5.92 | 50 | ||
2017-08-10 | 2017-06-30 | -14.4 | -3.3 | 11.1 | 77 | ||
2017-05-15 | 2017-03-31 | -10.8 | -16.8 | -6.0 | 55 | ||
2017-03-17 | 2016-12-31 | -11.92 | -10.95 | 0.97 | 8 | ||
2016-11-07 | 2016-09-30 | -23.2 | -16.35 | 6.85 | 29 | ||
2016-08-09 | 2016-06-30 | -25.95 | -19.95 | 6.0 | 23 | ||
2016-05-05 | 2016-03-31 | -27 | -31.5 | -4.5 | 16 | ||
2016-03-15 | 2015-12-31 | -41.25 | -88.5 | -47.25 | 114 | ||
2015-11-05 | 2015-09-30 | -51.5 | -31.5 | 20.0 | 38 | ||
2015-08-06 | 2015-06-30 | -46.24 | -25.5 | 20.74 | 44 | ||
2015-05-05 | 2015-03-31 | -54 | -76.5 | -22.5 | 41 | ||
2015-03-02 | 2014-12-31 | -62.7 | -48.0 | 14.7 | 23 | ||
2014-10-30 | 2014-09-30 | -51.3 | -72.0 | -20.7 | 40 | ||
2014-08-07 | 2014-06-30 | -44.7 | -60.0 | -15.3 | 34 | ||
2014-05-08 | 2014-03-31 | -59.25 | -73.5 | -14.25 | 24 | ||
2014-03-13 | 2013-12-31 | -53.5 | -70.5 | -17.0 | 31 | ||
2013-11-07 | 2013-09-30 | -63.37 | -67.5 | -4.13 | 6 | ||
2013-08-08 | 2013-06-30 | -61.5 | -69.0 | -7.5 | 12 | ||
2013-05-09 | 2013-03-31 | -67.5 | -75.0 | -7.5 | 11 | ||
2013-03-11 | 2012-12-31 | -80 | -150.0 | -70.0 | 87 | ||
2012-11-14 | 2012-09-30 | -75 | -90.0 | -15.0 | 20 | ||
2012-08-14 | 2012-06-30 | -120 | -75.0 | 45.0 | 37 | ||
2012-05-11 | 2012-03-31 | -120 | -120.0 | 0.0 | 0 | ||
2012-03-20 | 2011-12-31 | -101.25 | -285.0 | -183.75 | 181 | ||
2011-11-11 | 2011-09-30 | -165 | -120.0 | 45.0 | 27 | ||
2011-08-12 | 2011-06-30 | -141 | -195.0 | -54.0 | 38 | ||
2011-05-17 | 2011-03-31 | -116.25 | -210.0 | -93.75 | 80 | ||
2010-11-12 | 2010-09-30 | -120 | -195.0 | -75.0 | 62 | ||
2010-08-16 | 2010-06-30 | -95 | -165.0 | -70.0 | 73 | ||
2010-05-17 | 2010-03-31 | -75 | -180.0 | -105.0 | 140 |
Use Lisata Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lisata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lisata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Lisata Therapeutics Pair Trading
Lisata Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Lisata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lisata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lisata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lisata Therapeutics to buy it.
The correlation of Lisata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lisata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lisata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lisata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lisata Therapeutics position
In addition to having Lisata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Silver Thematic Idea Now
Silver
Companies involved in mining, production, and distribution of silver and silver goods. The Silver theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Silver Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
To fully project Lisata Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lisata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lisata Therapeutics' income statement, its balance sheet, and the statement of cash flows.